A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.

Kung AW, Pasion EG, Sofiyan M, Lau EM, Tay BK, Lam KS, Wilawan K, Ongphiphadhanakul B, Thiebaud D

Current medical research and opinion1 May 2006Cited by 25 (Europe PMC)

PMID16709314DOI10.1185/030079906x104768PepBankPUB-16709314

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

17 results from studies that gave the peptide. 17 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Asian postmenopausal women with osteoporosis, teriparatide increased lumbar spine BMD significantly more than calcitonin.
In plain wordsIn Asian women with osteoporosis, teriparatide increased spinal bone density more than calcitonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD versus calcitonin
Study
n = 104
Comparator
Salmon calcitonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 g/day as printed · subcutaneous · 6 monthsAs given in this study (human).
Measurements
P value
< 0.0001 NA
teriparatide versus calcitonin
Source sentences
Summary
Comparison of the two groups indicated that teriparatide treatment improved lumbar spine BMD statistically significantly more than calcitonin (p < 0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931402
02HumanRandomized controlled trialSafety outcome
In Asian postmenopausal women with osteoporosis, adverse event rates were similar with teriparatide and calcitonin.
In plain wordsIn Asian women with osteoporosis, adverse event rates were similar with teriparatide and calcitonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOverall adverse event rates
Study
n = 104
Comparator
Salmon calcitonin
Outcome group
Adverse events · Whole body
Studied dose
20 g/day as printed · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931407
03HumanRandomized controlled trialSafety outcome
In Asian postmenopausal women with osteoporosis, nausea rates were similar with teriparatide and calcitonin.
In plain wordsIn Asian women with osteoporosis, nausea rates were similar with teriparatide and calcitonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNausea
Study
n = 104
Comparator
Salmon calcitonin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
20 g/day as printed · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Nausea rate
13%
teriparatide
Nausea rate
23.2%
calcitonin
Nausea comparison P value
0.21 NA
teriparatide versus calcitonin
Source sentences
Summary
Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931408
04HumanRandomized controlled trialSafety outcome
In Asian postmenopausal women with osteoporosis, dizziness rates were similar with teriparatide and calcitonin.
In plain wordsIn Asian women with osteoporosis, dizziness rates were similar with teriparatide and calcitonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDizziness
Study
n = 104
Comparator
Salmon calcitonin
Outcome group
Adverse events · Nervous system and cognition
Studied dose
20 g/day as printed · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Dizziness rate
10.9%
teriparatide
Dizziness rate
21.4%
calcitonin
Dizziness comparison P value
0.19 NA
teriparatide versus calcitonin
Source sentences
Summary
Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931409
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal Asian women with osteoporosis, salmon calcitonin increased lumbar spine BMD significantly less than teriparatide (p < 0.0001).
In plain wordsIn women with osteoporosis, salmon calcitonin increased spinal bone density significantly less than teriparatide.
Peptide
Calcitonin-salmon
Outcome
DecreaseLumbar spine BMD versus teriparatide
Study
n = 104
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
p
< 0.0001
between groups
Source sentences
Summary
Comparison of the two groups indicated that teriparatide treatment improved lumbar spine BMD statistically significantly more than calcitonin (p < 0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931412
06HumanRandomized controlled trialSafety outcome
In postmenopausal Asian women with osteoporosis, adverse event rates were similar with salmon calcitonin and teriparatide.
In plain wordsIn women with osteoporosis, adverse event rates were similar with salmon calcitonin and teriparatide.
Peptide
Calcitonin-salmon
Outcome
No significant changeOverall adverse event rates
Study
n = 104
Comparator
Teriparatide
Outcome group
Adverse events · Whole body
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931417
07HumanRandomized controlled trialSafety outcome
In postmenopausal Asian women with osteoporosis, nausea rates were numerically higher with salmon calcitonin than teriparatide (23.2% versus 13.0%, p = 0.21).
In plain wordsIn women with osteoporosis, nausea rates were numerically higher with salmon calcitonin than teriparatide, without statistical significance.
Peptide
Calcitonin-salmon
Outcome
IncreaseNausea
Study
n = 104
Comparator
Teriparatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Nausea rate
23.2%
calcitonin
Nausea rate
13%
teriparatide
p
0.21
between groups
Source sentences
Summary
Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931418
08HumanRandomized controlled trialSafety outcome
In postmenopausal Asian women with osteoporosis, dizziness rates were numerically higher with salmon calcitonin than teriparatide (21.4% versus 10.9%, p = 0.19).
In plain wordsIn women with osteoporosis, dizziness rates were numerically higher with salmon calcitonin than teriparatide, without statistical significance.
Peptide
Calcitonin-salmon
Outcome
IncreaseDizziness
Study
n = 104
Comparator
Teriparatide
Outcome group
Adverse events · Nervous system and cognition
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Dizziness rate
21.4%
calcitonin
Dizziness rate
10.9%
teriparatide
p
0.19
between groups
Source sentences
Summary
Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931419
09HumanRandomized controlled trialEfficacy outcome
In Asian postmenopausal women with osteoporosis, teriparatide increased lumbar spine BMD from baseline.
In plain wordsIn Asian women with osteoporosis, teriparatide increased spinal bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD change from baseline
Study
n = 47
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 g/day as printed · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Mean lumbar spine BMD change
5.03%
teriparatide
SD of lumbar spine BMD change
4.77%
teriparatide
P value
< 0.0001 NA
teriparatide, change from baseline
Source sentences
Summary
Teriparatide was associated with a 5.03 +/- 4.77% increase in lumbar spine BMD (p < 0.0001, mean +/- SD change from baseline),
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931401
10HumanRandomized controlled trialEfficacy outcome
In Asian postmenopausal women with osteoporosis, teriparatide increased bone-specific alkaline phosphatase from baseline.
In plain wordsIn Asian women with osteoporosis, teriparatide increased bone-specific alkaline phosphatase from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone-specific alkaline phosphatase
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 g/day as printed · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Median BSAP change
55.9%
teriparatide
Source sentences
Summary
Serum bone-specific alkaline phosphatase (BSAP) increased by 55.9% (median change from baseline, p < 0.0001) in the teriparatide group, and remained stable with calcitonin (5.0% change, p = 0.24);
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931405
11HumanRandomized controlled trialEfficacy outcome
In Asian postmenopausal women with osteoporosis, teriparatide increased osteocalcin from baseline.
In plain wordsIn Asian women with osteoporosis, teriparatide increased osteocalcin from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteocalcin
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 g/day as printed · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Median osteocalcin change
156.15%
teriparatide
Source sentences
Summary
osteocalcin increased by 156.15% (median change from baseline, p < 0.0001) with teriparatide, and decreased with calcitonin (-15.25%, p = 0.03).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931406
12HumanNon-randomized trialEfficacy outcome
In postmenopausal Asian women with osteoporosis, salmon calcitonin increased lumbar spine BMD by 0.36 +/- 4.12% from baseline, without statistical significance (p = 0.16).
In plain wordsIn women with osteoporosis, spinal bone density increased slightly from baseline with salmon calcitonin, without statistical significance.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD change from baseline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Lumbar spine BMD mean change
0.36%
calcitonin
Lumbar spine BMD change SD
4.12%
calcitonin
p
0.16
versus baseline
Source sentences
Summary
whereas changes in lumbar spine BMD for patients on calcitonin were not statistically significant (mean change of 0.36 +/- 4.12%, p = 0.16).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931411
13HumanNon-randomized trialEfficacy outcome
In postmenopausal Asian women with osteoporosis, total hip BMD did not change significantly with salmon calcitonin.
In plain wordsIn women with osteoporosis, total hip bone density did not change significantly from baseline with salmon calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeTotal hip BMD change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
No statistically significant changes were observed for total hip or femoral neck BMD.
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931413
14HumanNon-randomized trialEfficacy outcome
In postmenopausal Asian women with osteoporosis, femoral neck BMD did not change significantly with salmon calcitonin.
In plain wordsIn women with osteoporosis, femoral neck bone density did not change significantly from baseline with salmon calcitonin.
Peptide
Calcitonin-salmon
Outcome
No significant changeFemoral neck BMD change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
No statistically significant changes were observed for total hip or femoral neck BMD.
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931414
15HumanNon-randomized trialEfficacy outcome
In postmenopausal Asian women with osteoporosis, serum BSAP changed by 5.0% from baseline with salmon calcitonin, without statistical significance (p = 0.24).
In plain wordsIn women with osteoporosis, serum BSAP increased from baseline with salmon calcitonin, without statistical significance.
Peptide
Calcitonin-salmon
Outcome
IncreaseSerum BSAP change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
BSAP median change
5%
calcitonin
p
0.24
versus baseline
Source sentences
Summary
Serum bone-specific alkaline phosphatase (BSAP) increased by 55.9% (median change from baseline, p < 0.0001) in the teriparatide group, and remained stable with calcitonin (5.0% change, p = 0.24)
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931415
16HumanNon-randomized trialEfficacy outcome
In postmenopausal Asian women with osteoporosis, osteocalcin decreased by 15.25% from baseline with salmon calcitonin (p = 0.03).
In plain wordsIn women with osteoporosis, osteocalcin decreased from baseline with salmon calcitonin.
Peptide
Calcitonin-salmon
Outcome
DecreaseOsteocalcin change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Osteocalcin median change
−15.25%
calcitonin
p
0.03
versus baseline
Source sentences
Summary
osteocalcin increased by 156.15% (median change from baseline, p < 0.0001) with teriparatide, and decreased with calcitonin (-15.25%, p = 0.03).
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931416
17HumanNon-randomized trialSafety outcome
In postmenopausal Asian women with osteoporosis, no clinically relevant laboratory parameter changes were observed with salmon calcitonin.
In plain wordsIn women with osteoporosis, laboratory parameters showed no clinically relevant changes from baseline with salmon calcitonin.
Peptide
Calcitonin-salmon
Outcome
Direction not reportedLaboratory parameter changes
Study
n: not reported in source
Comparator
Baseline
Outcome group
Adverse events · Whole body
Studied dose
100 IU/day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
There were no clinically relevant changes observed in laboratory parameters.
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
Report a problemFND-1670931420

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

18HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In Asian postmenopausal women with osteoporosis, no significant total hip BMD change occurred during the teriparatide versus calcitonin trial.
In plain wordsIn Asian women with osteoporosis, total hip bone density did not change significantly during the teriparatide versus calcitonin trial.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
No statistically significant changes were observed for total hip or femoral neck BMD.
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1670931403
19HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In Asian postmenopausal women with osteoporosis, no significant femoral neck BMD change occurred during the teriparatide versus calcitonin trial.
In plain wordsIn Asian women with osteoporosis, femoral neck bone density did not change significantly during the teriparatide versus calcitonin trial.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
No statistically significant changes were observed for total hip or femoral neck BMD.
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1670931404
20HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome
In Asian postmenopausal women with osteoporosis, laboratory parameters showed no clinically relevant changes during the teriparatide versus calcitonin trial.
In plain wordsIn Asian women with osteoporosis, laboratory tests showed no clinically relevant changes during the teriparatide versus calcitonin trial.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLaboratory parameters
Study
n: not reported in source
Comparator
Baseline
Outcome group
Adverse events · Whole body
Source sentences
Summary
There were no clinically relevant changes observed in laboratory parameters.
3 context sentences(design, population, supporting numbers)
Summary · context
As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
Summary · context
A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand.
Summary · context
Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1670931410

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.